Biophysical Characterization of Proteins in Developing Biopharmaceuticals is concerned with the analysis and characterization of the higher-order structure (HOS) or conformation of protein based drugs. Starting from the very basics of protein structure this book takes the reader on a journey on how to best achieve this goal using the key relevant and practical methods commonly employed in the biopharmaceutical industry today as well as up and coming promising methods that are now gaining increasing attention.
As a general resource guide this book has been written with the intent to help today's industrial scientists working in the biopharmaceutical industry or the scientists of tomorrow who are planning a career in this industry on how to successfully implement these biophysical methodologies. In so doing a keen focus is placed on understanding the capability of these methodologies in terms of what information they can deliver. Aspects of how to best acquire this biophysical information on these very complex drug molecules, while avoiding potential pitfalls, in order to make concise, well informed productive decisions about their development are key points that are also covered.
- Presents the reader with a clear understanding of the real world issues and challenges in using these methods.
- Highlights the capabilities and limitations of each method.
- Discusses how to best analyze the data generated from these methods.
- Points out what one needs to look for to avoid making faulty conclusions and mistakes.
- In total it provides a check list or road map that empowers the industrial scientists as to what they need to be concerned with in order to effectively do their part in successfully developing these new drugs in an efficient and cost effective manner.
Inhaltsverzeichnis
1;Front Cover;1 2;Biophysical Characterization of Proteins in Developing Biopharmaceuticals;4 3;Copyright;5 4;Contents;6 5;List of Contributors;10 6;About the Editors;12 7;Preface;14 8;List of Abbreviations and Symbols;18 9;Chapter 1 - The Complexity of Protein Structure and the Challenges it Poses in Developing Biopharmaceuticals;24 9.1;1.1 THE BASICS OF PROTEIN HIGHER-ORDER STRUCTURE (HOS);24 9.2;1.2 THE SEARCH FOR HOW PROTEINS ATTAIN THEIR CORRECT HOS: THE PROTEIN FOLDING PROBLEM;31 9.3;1.3 SURPRISES IN THE WORLD OF PROTEIN FOLDING: INTRINSICALLY DISORDERED OR UNSTRUCTURED PROTEINS (AN APPARENT CHALLENGE TO THE ...;35 9.4;1.4 PROTEINS AND THE BIOPHARMACEUTICAL INDUSTRY: PROBLEMS AND CHALLENGES;35 9.5;1.5 CONCLUSION;40 9.6;References;41 9.7;Further Reading;44 10;Chapter 2 - Biophysical Characterization and Its Role in the Biopharmaceutical Industry;46 10.1;2.1 DRUG DEVELOPMENT PROCESS;46 10.2;2.2 PROTEIN DRUGS (BIOPHARMACEUTICALS);48 10.3;2.3 THE ROLE OF BIOPHYSICAL CHARACTERIZATION IN BIOPHARMACEUTICAL DRUG DEVELOPMENT;50 10.4;2.4 THE CHALLENGES IN CONDUCTING BIOPHYSICAL MEASUREMENTS TO DETECT CHANGES IN A PROTEIN DRUG'S HOS;62 10.5;2.5 REGULATORY NEEDS AND CONSIDERATIONS;65 10.6;References;66 10.7;Further Reading;70 11;Chapter 3 - Biopharmaceutical Industry's Biophysical Toolbox;72 11.1;3.1 ATTRIBUTES OF A SINGLE BIOPHYSICAL TOOL TO CHARACTERIZE AND DETECT CHANGES IN THE HIGHER ORDER STRUCTURE OF A BIOPHARMACEUTICAL;72 11.2;3.2 STUDYING THE BIOPHYSICAL PROPERTIES OF A BIOPHARMACEUTICAL AS AN INDIRECT APPROACH FOR CHARACTERIZING CHANGES IN ITS HOS;74 11.3;3.3 GENERAL CONSIDERATIONS IN ANALYZING THE BIOPHYSICAL PROPERTIES OF BIOPHARMACEUTICALS;77 11.4;3.4 THE UTILITY OF USING STRESS TO MONITOR CHANGES IN THE HOS PROFILE OF A PROTEIN DRUG;81 11.5;3.5 PRESENT BIOPHYSICAL TOOLBOX;82 11.6;3.6 CONCLUSION;97 11.7;References;97 11.8;Further Reading;101 12;Chapter 4 - An Introduction and Hierarchical Organization of the Biophysical Tool in Section II;102 12.1;4.1 INTRODUC
TION;102 12.2;4.2 THE STANDARD CLASS OF BIOPHYSICAL TOOLS USED IN THE BIOPHARMACEUTICAL INDUSTRY;104 12.3;4.3 THE ADVANCED CLASS OF BIOPHYSICAL TOOLS USED IN THE BIOPHARMACEUTICAL INDUSTRY;105 12.4;4.4 AN OVERVIEW OF SECTION II;107 12.5;References;107 12.6;Further Reading;108 13;Chapter 5 - The Value of UV, Fluorescence, and FTIR Spectroscopy in Biopharmaceutical Development;110 13.1;5.1 INTRODUCTION;110 13.2;5.2 THE ORIGINS OF ELECTRONIC ABSORPTION, FLUORESCENCE, AND FT-IR SPECTROSCOPY;111 13.3;5.3 CONFORMATIONAL ANALYSIS OF PROTEINS IN SOLUTION;115 13.4;5.4 OPTICAL SPECTROSCOPY AND PRODUCT COMPARABILITY;118 13.5;5.5 OPTICAL SPECTROSCOPY AND HIGH-THROUGHPUT METHODS;122 13.6;5.6 SOLID-STATE MEASUREMENTS;125 13.7;5.7 CONCLUSIONS;127 13.8;References;128 14;Chapter 6 - Circular Dichroism Spectroscopy for Protein Characterization: Biopharmaceutical Applications;132 14.1;6.1 INTRODUCTION;132 14.2;6.2 INSTRUMENTATION;137 14.3;6.3 DATA GENERATED;138 14.4;6.4 GUIDE TO COLLECTING GOOD DATA;139 14.5;6.5 DATA PROCESSING AND ANALYSES;150 14.6;6.6 ROLE IN THE RESEARCH INDUSTRY;153 14.7;6.7 TECHNOLOGY AVAILABILITY;154 14.8;6.8 FUTURE DEVELOPMENTS;156 14.9;Acknowledgments;157 14.10;References;157 14.11;Further Reading;159 15;Chapter 7 - Size-Exclusion Chromatograph (SEC) in Biopharmaceutical Process Development;162 15.1;7.1 INTRODUCTION;162 15.2;7.2 BASIC THEORY OF NORMAL OR IDEAL SEC;163 15.3;7.3 MAXIMIZING SEC SEPARATION BY ENHANCING THE USAGE OF PORE VOLUME AND PORE STRUCTURE;167 15.4;7.4 CHARACTERISTICS OF PORE STRUCTURE;169 15.5;7.5 NONIDEAL SEC CHROMATOGRAPHY;170 15.6;7.6 ASSESSING AND MAINTAINING AN OPTIMUM SEC CHROMATOGRAPHY METHOD;174 15.7;7.7 DETECTORS;176 15.8;7.8 MULTIDETECTOR SEC;183 15.9;7.9 AGGREGATION;187 15.10;7.10 TECHNOLOGY ADVANCES;188 15.11;7.11 CONCLUSION;188 15.12;References;189 16;Chapter 8 - Scattering Techniques for the Characterization of Biopharmaceuticals;194 16.1;8.1 INTRODUCTION;194 16.2;8.2 INTENSITY- AND TIME-DEPENDENT LIGHT SCATTERING;195 16.3;8.3
GENERAL COMMENT CONCERNING SLS AND DLS;208 16.4;8.4 THE DUST PROBLEM IN SLS AND DLS;209 16.5;8.5 X-RAY SCATTERING: CHARACTERIZATION OF PROTEINS IN SOLUTION USING SMALL-ANGLE X-RAY SCATTERING;210 16.6;References;229 17;Chapter 9 - Characterizing Biopharmaceuticals using Analytical Ultracentrifugation;234 17.1;9.1 INTRODUCTION;234 17.2;9.2 UNIQUE FEATURES OF THE ANALYTICAL ULTRACENTRIFUGE THAT MAKE IT DIFFERENT FROM OTHER CENTRIFUGES;235 17.3;9.3 THEORY;236 17.4;9.4 UTILITY OF AUC IN THE BIOPHARMACEUTICAL INDUSTRY;240 17.5;9.5 BOUNDARY SV-AUC;242 17.6;9.6 BAND SV-AUC;262 17.7;9.7 SEDIMENTATION EQUILIBRIUM, SE-AUC;264 17.8;9.8 DENSITY-GRADIENT SE-AUC;266 17.9;9.9 AUC DETECTORS;268 17.10;9.10 MISCELLANEOUS HELPFUL INFORMATION ABOUT CONDUCTING AUC EXPERIMENTS;275 17.11;9.11 CONCLUSION;277 17.12;References;278 17.13;Further Reading;282 18;Chapter 10 - Subvisible and Visible Particle Analysis in Biopharmaceutical Research and Development;284 18.1;10.1 INTRODUCTION;284 18.2;10.2 OVERVIEW OF ANALYTICAL METHODS;285 18.3;10.3 GENERAL RECOMMENDATIONS AND PITFALLS FOR PARTICLE ANALYSIS;302 18.4;10.4 OUTLOOK AND CONCLUSIONS;305 18.5;References;306 19;Chapter 11 - Differential Scanning Calorimetry in the Biopharmaceutical Sciences;310 19.1;11.1 BACKGROUND;310 19.2;11.2 DSC INSTRUMENTS;316 19.3;11.3 PRACTICAL CONSIDERATIONS FOR DSC USE;318 19.4;11.4 DATA ANALYSIS;322 19.5;11.5 APPLICATIONS OF SOLUTION DSC IN BIOPHARMACEUTICAL DISCOVERY AND DEVELOPMENT;323 19.6;11.6 APPLICATIONS OF SOLID-SAMPLE DSC IN BIOPHARMACEUTICAL DISCOVERY AND DEVELOPMENT;325 19.7;11.7 CONCLUSIONS;327 19.8;Acknowledgments;327 19.9;References;327 20;Chapter 12 - Biophysical Mass Spectrometry for Biopharmaceutical Process Development: Focus on Hydrogen/Deuterium Exchange;330 20.1;12.1 INTRODUCTION;330 20.2;12.2 SYNOPSIS OF THE TECHNIQUE;334 20.3;12.3 MECHANISM OF EXCHANGE;335 20.4;12.4 ADVANCES IN THE TECHNIQUE;337 20.5;12.5 COMMERCIALIZATION;345 20.6;12.6 APPLICATIONS IN THE BIOPHARMACEUTICAL INDUSTRY;346 20.7
;12.7 FUTURE PERSPECTIVE;353 20.8;Acknowledgments;354 20.9;References;354 21;Chapter 13 - One- and Two-Dimensional NMR Techniques for Biopharmaceuticals;364 21.1;13.1 PHYSICAL BASIS OF THE TECHNIQUE;364 21.2;13.2 THE APPROPRIATE TECHNIQUE FOR A PARTICULAR PROBLEM;379 21.3;13.3 METHOD REQUIREMENTS AND PERFORMANCE;384 21.4;13.4 DATA PROCESSING (PROCEDURES);396 21.5;13.5 ROLE IN RESEARCH VS PROCESS DEVELOPMENT;398 21.6;13.6 TECHNOLOGY UPDATE: RECENT AND FUTURE ADVANCES AND UNIQUE APPLICATIONS;400 21.7;References;401 21.8;Further Reading;405 22;Chapter 14 - Biophysical Characterization: An Integral Part of the Totality of the Evidence Concept;408 22.1;14.1 BIOPHARMACEUTICAL DEVELOPMENT;408 22.2;14.2 AN INTRODUCTION TO THE TOTALITY OF THE EVIDENCE AND ITS MORE GLOBAL MEANING IN DEVELOPING BIOPHARMACEUTICALS;409 22.3;14.3 BIOPHYSICAL CHARACTERIZATION IN DEVELOPING PROTEIN BIOPHARMACEUTICALS;411 22.4;14.4 BUILDING A BIOPHARMACEUTICAL'S BIOPHYSICAL FINGERPRINT;412 22.5;14.5 DETECTING SMALL DIFFERENCES IN BIOPHARMACEUTICALS VIA BIOPHYSICAL CHARACTERIZATION MEASUREMENTS;416 22.6;14.6 CONCLUSION;418 22.7;References;418 23;Index;420